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Background: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. Few
studies have focused on the quality of life (QoL) associated medical costs for COPD in China.
Methods: A cross-sectional survey of 678 COPD patients was conducted in four major cities (Beijing, Shanghai,
Guangzhou and Chengdu), China, in 2011. Data on socio-demographic information, health conditions and medical
costs were collected through a face-to-face interview combined with medical record searching. The EuroQol (EQ-5D)
health questionnaire was applied to assess the QoL of COPD patients.
Results: Among 678 patients with COPD, nearly 40% had difficulties in mobility, usual activities and pain/discomfort,
one third had various degrees of anxiety/depression, and one fifth had difficulties in self-care. The COPD patients had a
median utility score of 0.768 and a median visual analog scale score of 70. The degree of difficulties in any dimensions
significantly increased, and utility and health scores decreased with severity of the disease. Age, gender and disease
severity were significantly associated with the quality of life after taking other covariates into consideration.
Poorer QoL was a significant indicator of higher direct medical costs for COPD patients.
Conclusion: Impaired quality of life was significantly linked to increased medical costs for COPD patients and
could be an important measure for policy- and decision-making in COPD care.
Keywords: Chronic obstructive pulmonary disease, Quality of life, A cross-sectional study, Medical costBackground
Chronic obstructive pulmonary disease (COPD) is ranked
the fourth of the 10 leading causes of death, and killed ap-
proximately 3 million people (5.8% of all deaths) globally
in 2011 [1]. Compared to a decrease in cardiovascular
mortality and stabilization of cancer mortality worldwide,
mortality from COPD is increasing in European countries
[2]. In China, the prevalence of COPD was as high as 8.2%
in 2008 for adults aged 40 years or above based on data
from a national survey [3].
COPD is a well-recognized high economic burden dis-
ease. In 2010, the costs of COPD were projected to be
approximately US$50 billion, which included $20 billion
in indirect costs and $30 billion indirect health care ex-
penditures in the U.S. [4]. How to reduce such enor-
mous costs for COPD care is an unmet challenge to all
countries.* Correspondence: cwfu@shmu.edu.cn
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unless otherwise stated.COPD is characterized by airflow limitation that is not
fully reversible. It is also an irreversible respiratory dis-
ease that can seriously reduce people’s physical capacity,
social functioning and subjective well-being. In order to
assess how COPD patients themselves perceive their
lives, various forms of instruments are used, most often
based on self-report [5]. The EuroQol (EQ-5D) is one
instrument to measure Health related quality of life
(HRQoL) that has been calibrated with different popula-
tions, and has been used widely. It is brief and simple,
and patients can easily understand and complete. The
EQ-5D is also easy to score and interpret. Assessments
of HRQoL using generic instruments like the EQ-5D
allow for comparisons with other chronic diseases as
well as comparisons with healthy populations to estimate
the incremental burden of COPD [6].
HRQoL is a common measure used in the evaluation
of healthcare interventions. A number of studies found
that proper health interventions could both improve the
quality of life (QoL) and reduce the medical costs ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for subsequent COPD exacerbation, hospitalization and
mortality, and is related to the severity of COPD, which all
are measures associated with a high healthcare expend-
iture [9-12]. Also, QoL is strongly associated with invest-
ment beliefs and their behaviors including healthcare
seeking [13-16]. Therefore, QoL may be a better predictor
for medical costs than others, and can be used for policy-
and decision-making. So far, there has been limited infor-
mation on the QoL for COPD patients in China and the
relationship between QoL and direct medical costs has
not been clear. This study intended to understand the
QoL of COPD patients and the relationship to medical
direct costs in China.
Materials and methods
Study site and subjects
A cross-sectional study was carried out in Beijing,
Guangzhou, Shanghai and Chengdu from March to
June 2011. Fifteen community health centers (or hospitals)
were involved to recruit subjects from the communities.
Patient inclusion criteria included that a patient: 1) Met
the diagnosis criterion of COPD provided by the Chinese
Society of Respiratory Diseases in 2007 [17]; 2) Received
the assessment of lung function at least once in the past
12 months; 3) was able to provide informed consent and
medical chart; 4) was able to complete the questionnaire
interview; and 5) was a local resident who lived in the city
for at least 2 years. Patients who had any unstable comor-
bidities or any severe conditions needed to be treated as in-
patients were excluded from the study. All subjects had
lung function testing during the survey. Totally, 678 out of
721 eligible COPD patients were included in this study,
with a response rate of 94%.
Questionnaire
The EQ-5D health questionnaire was applied to assess
the QoL for COPD patients [7,9]. The self-classifier con-
sists of five dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression), each with three
levels of response (level 1 = no problems, level 2 = some
problems, or level 3 = inability or extreme problems). The
utility score is typically interpreted along a continuum
where 1 represents best possible health and 0 represents
dead, with some health states considered worse than dead.
In addition to the self-classifier, the EQ-5D contains a
20 cm visual analog scale (VAS) ranging from 0 (worst im-
aginable health) to 100 (best imaginable health) along
which the respondent rates their health today. The index-
based utility scores can be used to compare a burden
of disease across different conditions and facilitate the
calculation of quality adjusted life years (QALYs) that
are incorporated into economic evaluations of health care
interventions [8]. A single summary score was generatedby applying societal preference weights to a health state
classifier completed by patients.
Data collection and quality control
Data collectors were health workers who were recruited
from each study site and trained by academic investiga-
tors. The study subjects were face-to-face interviewed
with a structured questionnaire, and their medical charts
were also reviewed and the details of medical care
utilization were obtained. The data of medical costs were
collected from their medical charts and bill payments.
All questionnaires were double-checked while they
were filled out. An interview was conducted by two in-
vestigators - one was in charge of the interview and an-
other had a double-check and made sure that the interview
information was recorded correctly, as one measure of
quality control. Fifteen subjects were randomly sampled in
each city and a total sixty subjects were re-interviewed by
the telephone after 2–3 months to check the reproducibil-
ity of the questionnaire information for quality control.
The key variables included sex, smoking status, disease se-
verity, number of outpatient visits and hospital admission
information. The reliability was satisfactory with Kappa
values of 0.93 - 1.00 for key categorical variables and intra-
class correlation coefficients of 0.96 - 0.98 for key continu-
ous variables.
Informed consent
A written informed consent was obtained from all sub-
jects. They were free to withdraw from the study at any
time with no negative consequences. The ethic approval
for this study was issued by the Institutional Review
Board of the Fudan University School of Public Health.
Data analysis
Subjects were grouped into four categories of severity
(mild, moderate, severe and very severe) for COPD
based on the criteria established by the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) [18]. An-
nual direct medical costs for each patient were calculated
based on the total expenditures in the past 12 months of
this interview and records for treating COPD, including
co-payments, diagnoses, treatments, diagnostic tests, pre-
scription drugs, medical supplies, and use of oxygen in
both outpatient visits and hospital admissions.
All the data were double input into a database estab-
lished through EpiData3.1 Chinese version. Statistical
analysis was completed by using SPSS16. Chi-square test
was used for testing the differences of five dimensions,
and Kruskal-Wallis test for comparing the utility scores
and VAS scores. The estimation of EQ-5D utility was
based on the Japanese population index set [19]. The an-
nual direct medical costs and the QoL of EQ-5D utilities
were analysed by comparing the top 25th percentile with
Table 1 Demographic and clinical characteristics of COPD patients
Characteristics Beijing (%) Guangzhou (%) Shanghai (%) Chengdu (%) Total (%)
Age (years)* 73.3 (71.6 ± 10.3) 68.8 (68.0 ± 8.6) 69.6 (68.8 ± 11.1) 74.2 (73.3 ± 9.4) 71.8 (70.4 ± 10.1)
Gender (Male) 100 (58.8) 152 (86.9) 125 (74.4) 117 (70.9) 494 (72.9)
Education (<9 years) 53 (31.4) 37 (21.1) 36 (21.4) 53 (32.1) 179 (26.4)
Medical insurance 166 (97.6) 156 (89.1) 164 (97.6) 163 (98.8) 649 (95.7)
Smoking 40 (23.7) 40 (22.9) 25 (14.9) 26 (15.8) 131 (19.4)
Age at diagnosis (years)* 64.0 (61.4 ± 13.9) 66.5 (64.7 ± 9.7) 61.9 (61.3 ± 13.3) 60.4 (59.4 ± 15.5) 63.9 (61.7 ± 13.3)
Course of illness (years)* 6.6 (10.2 ± 12.2) 1.4 (3.2 ± 4.6) 3.8 (7.6 ± 9.4) 8.6 (13.9 ± 14.2) 3.8 (8.7 ± 11.3)
Family history 39 (23.1) 40 (22.9) 38 (22.6) 61 (37.2) 178 (26.3)
FEV1 (liter)* 1.5 (1.4 ± 0.5) 1.4 (1.5 ± 1.0) 1.2 (2.2 ± 2.2) 1.1 (1.2 ± 0.7) 1.3 (1.6 ± 1.3)
FEV1% predicted* 58.7 (57.4 ± 19.5) 56.0 (57.8 ± 24.6) 49.0 (52.1 ± 22.4) 47.0 (49.9 ± 24.4) 53.0 (54.5 ± 23.0)
Co-morbidities 158 (92.9) 96 (54.9) 130 (77.4) 150 (91.5) 534 (78.9)
Current severity level
Mild 31 (18.2) 35 (20.0) 37 (22.0) 37 (22.4) 140 (20.6)
Moderate 86 (50.6) 79 (45.1) 61 (36.3) 70 (42.4) 296 (43.7)
Severe 40 (23.5) 39 (22.3) 57 (33.9) 45 (27.3) 181 (26.7)
Very severe 13 (7.6) 22 (12.6) 13 (7.7) 13 (7.9) 61 (9.0)
Total 170 (100) 175 (100) 168 (100) 165 (100) 678 (100)
*Median (Mean ± standard deviation).
Abbreviations: FEV1 forced expiratory volume in one second, FEV1% predicted the percentiles of forced expiratory volume in one second to the predicted value.
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the associations of factors with healthcare costs and
QoL were assessed by calculating crude and adjusted
odds ratios (OR) and 95% confidential intervals (CI).
Spearman’s correlations were calculated for the relation-
ships among QoL and annual direct medical costs. An
alpha level of ≤0.05 (two sides) was considered to be sta-
tistically significant.
Results
The general and clinical characteristics
Of the 678 participants, 72.9% were male. A majority of
them were retired with an average age of 70.4 ± 10.1 years.
Three quarters (74.6%) of them had received 9 years ofTable 2 Distribution of quality of life measure for COPD patients
Current
severity
Mobility (%)* Self-care (%)* Usual
activities (%)*
Pain/Discomfo
1 2 3 1 2 3 1 2 3 1 2
Mild 80.6 19.4 0.0 93.5 6.5 0.0 86.3 12.9 0.7 76.3 23.0
Moderate 67.6 29.1 3.4 85.8 11.1 3.0 67.6 27.4 5.1 62.8 35.1
Severe 44.8 52.5 2.8 75.1 22.1 2.8 44.8 48.1 7.2 54.7 42.5
Very severe 31.1 65.6 3.3 65.6 29.5 4.9 32.8 59.0 8.2 47.5 47.5
p value <0.001 0.016 <0.001 <0.001
Total 60.9 36.6 2.5 82.7 14.8 2.5 62.2 32.8 5.0 62.0 35.7
*1 = no problem; 2 =moderate or some problem; 3 = inability or extreme problem.
**Median (Mean± standard deviation).
Abbreviation: VAS visual analog scale.education or more. Of them, 19.4% were current smokers,
and almost all of them (95.7%) had at least one type of
medical insurances. The median age at the diagnosis of
COPD was 63.9 years (means: 61.6 ± 13.7 years) and the
median duration of COPD was 3.8 years (means: 8.8 ±
11.6 years). About one quarter had a family history of
chronic lung diseases, and most of them (79%) had at
least one co-morbid chronic disease. The median forced
expiratory volume in one second (FEV1) was 1.3 liters
(mean: 1.6 ± 1.3 liters) and the median FEV1% predicted
was 53.0 (mean: 54.5 ± 23.0). According to the criteria of
GOLD, 20.6% were in mild stage, 43.7% in moderate stage,
26.7% in severe stage, and 9.0% in very severe stage.
(Table 1).by current severity levels
rt (%)* Anxiety/depression (%)* VAS score** Utilities score**
3 1 2 3
0.7 72.7 26.6 0.7 70.0 (71.8 ± 13.3) 0.848 (0.786 ± 0.085)
2.0 73.0 24.7 2.4 70.0 (67.1 ± 16.7) 0.773 (0.734 ± 0.158)
2.8 67.4 30.4 2.2 67.0 (63.5 ± 16.3) 0.724 (0.691 ± 0.155)
4.9 63.9 31.1 4.9 60.0 (61.3 ± 15.8) 0.675 (0.655 ± 0.151)
<0.001 <0.001 <0.001
2.2 70.6 27.2 2.2 70.0(66.6 ± 16.2) 0.768 (0.726 ± 0.150)
Table 3 Factors associated with utilities of EQ-5D in COPD patients
Variables Top 25% Low 75% cOR (95% CI) p value aOR (95% CI)* p value*
Age (years) - - 0.96 (0.95,0.98) <0.001 0.98 (0.96,0.99) 0.012
Gender
Male 175 318 1.48 (1.02,2.14) 0.041 1.65 (1.06,2.58) 0.028
Female 50 134 1.00 - 1.00 -
Current severity
Mild 72 67 12.04 (4.55,31.86) <0.001 14.76 (5.33,40.89) <0.001
Moderate 108 188 6.43 (2.50,16.55) <0.001 7.15 (2.69,18.97) <0.001
Severe 40 141 3.18 (1.19,8.46) 0.021 3.43 (1.25,9.38) 0.016
Very severe 5 56 1.00 - 1.00 -
Total 225 452 - - - -
*Variables included in the logistic regression model: study site, average household income, having medical insurance(s), duration of COPD and presence
of comorbidities.
Abbreviations: aOR adjusted odds ratio, cOR crude odds ratio, CI confidence interval, COPD chronic obstructive pulmonary disease.
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Based on information collected using the EQ-5D ques-
tionnaire, nearly 40% of COPD subjects had difficulties
in mobility, usual activities and pain/discomfort, one
third had anxiety/depression and one fifth had difficul-
ties in self-care (Table 2). The median of utility score
was 0.768 and the median of VAS score was 70. The de-
gree of difficulties significantly increased with the severity
of COPD while the utility and health scores decreased.
Logistic regression analysis showed that age and gen-
der, severity of COPD were significantly associated with
the quality of life for COPD patients after adjusting for
household income, having a medical insurance, duration
of COPD, presence of a comorbid condition and study site
(Table 3).
QoL and annual direct medical costs
As shown in Table 4, the QoL of patients was inversely
related to the annual direct medical costs for COPD
care.. After adjustment for study site, age, gender, house-
hold income, severity and duration of COPD, having a
medical insurance and having a co-morbid condition,
the association was less strong but remained significant.
Further, annual direct medical costs were negatively as-
sociated with both VAS scores (r = −0.198, p < 0.001) and
utility scores (r = −0.336, p < 0.001), and also statistically
associated with five dimensions including mobility (r = 0.347,Table 4 The relationship between direct medical costs for CO
Utilities of EQ5D Annual direct medical cost cOR (95%
Top 25% Lower 75%
Lower 75% 139 305 3.28
(2.09,5.13)
Top 25% 27 194 1.00
*Variables included in the logistic regression model: study site, age, gender, househ
presence of comorbidities.
Abbreviations: aOR adjusted odds ratio, cOR crude odds ratio, CI confidence intervap < 0.001), self-care (r = 0.310, p < 0.001) usual activities
(r = 0.376, p < 0.001), pain/discomfort (r = 0.166, p < 0.001)
and anxiety/depression (r = 0.106, p = 0.006).Discussion
Impaired QoL for COPD patients
COPD is significantly associated with lower QoL, and
QoL has been recognized as an important outcome for
COPD. Patient reported outcomes such as health status
and quality of life are accepted as routine measures in
clinical studies, particularly in respiratory-related chronic
conditions [20-22]. In this study, we observed impaired
quality of life for COPD patients living in urban China
using the EQ-5D, and the utility and VAS scores declined
with the severity of COPD, which were similar to the re-
sults from the UK and the U.S. according to the utility
and VAS scores [10,23,24].QoL in COPD and possible related factors
Age and gender and severity of COPD were independent
factors significantly associated with the quality of life for
COPD patients after adjusting for covariates. In urban
China, younger and male patients had higher propor-
tions to have better utility scores, which was similar to
the results from previous studies [4,20,25,26]. This result
suggested that more attentions should be paid to olderPD care and quality of life of patients
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l, COPD chronic obstructive pulmonary disease.
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tions to improve their QoL.
In addition, as shown in Tables 2 and 3, the severity of
COPD was significantly related to the EQ-5D utility
scores, VAS scores and each dimension of EQ-5D. It is
expected that the QoL in COPD patients decreased with
disease severity as reported in the previous studies
[23,27-29]. The distinction in utility scores was relatively
small between the GOLD stages I and II groups, which
was also similar to previous observations [30]. The clas-
sification of GOLD stage is based on the levels of forced ex-
piratory volume in one second, which are only weakly
correlated with the EQ-5D utility scores [24,31]. The limited
ability to distinguish between milder stages of disease may
be a limitation in the discriminative ability of the EQ-5D
compared to some disease-specific instruments like the St.
George’s Respiratory Questionnaire [24,25,32].
QoL and direct medical costs for COPD
In this study, it was observed that patients with poorer
QoL had higher direct medical costs for COPD care
than those with better QoL, suggesting that to improve
QoL may help reduce direct medical costs for COPD pa-
tients. QoL is likely an independent and important meas-
ure for subsequent COPD exacerbation, hospitalization,
and mortality, and disease severity is associated with a
high healthcare expenditure [10-12]. Further, all five di-
mensions of EQ-5D had positive correlations to annual
direct medical costs, especially for two dimensions of mo-
bility and usual activities. The dimension of anxiety/
depression had a relatively low correlation coefficient,
As an important part of QoL, anxiety or depressive moods
are strongly associated with investment beliefs. They have
been shown to be a primary predictor of physically active
behavior, and physically active behavior can help improve
HRQoL and save COPD medication costs [13-16]. The
link between QoL and medical costs due to COPD in-
forms health care professionals and health policy makers
changes in QoL affecting direct medical costs and helps in
designing interventions to improve the QoL of COPD
patients.
The strengths and limitations of our study should be
noted. This was a hospital-based cross-sectional study in
urban China. This study carried out in four metropolitan
areas, with a high response rate. Quality control was
carefully planned and conducted. The QoL could well
reflect the current status of Chinese COPD patients liv-
ing in major urban areas. An inverse relationship be-
tween QoL of patients and direct medical costs for
COPD care had not been previously studied in China.
Although this is a cross-sectional study and the evidence
is weak for possible causal association, it is not likely
that a higher cost for COPD healthcare would result in
lower QoL for COPD patients. Another limitation of thestudy is that a random sampling method was not used,
and therefore, a caution is needed for a generalization to
broader population. Also, in this study, there may be a
recall bias for self-reporting information. Some informa-
tion was confirmed by checking their medical records.
The estimation of the EQ-5D utility was based on the
Japanese population index set since a Chinese popula-
tion index set was unavailable. Among three index sets
of the EQ-5D utility most frequently used, the Japanese
one as compared with American and British ones
seemed to more appropriate for Chinese population.
Conclusion
We measured impaired quality of life for COPD patients
living in urban China using the EQ-5D. Age, gender and
severity stages of COPD were associated with patients’
QoL. The QoL of patients had a strong negative correl-
ation with direct medical costs for COPD care, which
suggests that QoL can be an important measure for
COPD care, and improving QoL would reduce direct
medical costs.
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